TELIX Prostac study
A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium-177 rosopatamab tetraxetan plus standard of care versus standard of care alone for patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition.
Trial overview
Disease
Prostate cancer
Topic
Interventional
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Description
A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium-177 rosopatamab tetraxetan plus standard of care versus standard of care alone for patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition.
Study details
Trial status
Opening March 2026
Location
Principal Investigator
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.